Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2021

Feb. 28, 2022

Jun. 30, 2021

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Dec. 31, 2021

Document Fiscal Year Focus

2021

Document Fiscal Period Focus

FY

Entity Registrant Name

Compass Therapeutics, Inc.

Entity Central Index Key

0001738021

Current Fiscal Year End Date

--12-31

Entity Filer Category

Non-accelerated Filer

Entity Small Business

true

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

ICFR Auditor Attestation Flag

false

Entity Common Stock, Shares Outstanding

101,302,594

Entity Public Float

$ 180

Entity Shell Company

false

Entity Well-known Seasoned Issuer

No

Entity Voluntary Filers

Yes

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity File Number

000-55939

Entity Tax Identification Number

82-4876496

Entity Address, Address Line One

80 Guest Street

Entity Address, Address Line Two

Suite 601

Entity Address, City or Town

Boston

Entity Address, State or Province

MA

Entity Address, Postal Zip Code

02135

City Area Code

617

Local Phone Number

500-8099

Entity Incorporation, State or Country Code

DE

Document Annual Report

true

Document Transition Report

false

Title of each class

Common Stock, $0.0001 par value per share

Trading Symbol

CMPX

Security Exchange Name

NASDAQ

Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

Auditor Firm ID

596

Auditor Name

CohnReznick LLP

Auditor Location

Melville, NY U.S.A